Moteur de recherche d’entreprises européennes

Financement de l’UE (25,4 M €) : Relier l’évaluation de la mobilité numérique aux résultats cliniques pour l’approbation réglementaire et clinique Hor 01/04/2019 Programme de recherche et d'innovation de l'UE « Horizon »

Vue d’ensemble

Texte

Relier l’évaluation de la mobilité numérique aux résultats cliniques pour l’approbation réglementaire et clinique

Optimal treatment of the impaired mobility resulting from ageing and chronic disease is one of the 21st century's greatest challenges facing patients, society, governments, healthcare services, and science. New interventions are a key focus. However, to accelerate their development, we need better ways to detect and measure mobility loss. Digital technology, including body worn sensors, has the potential to revolutionise mobility assessment. The overarching objectives of MOBILISE-D are threefold: to deliver a valid solution (consisting of sensor, algorithms, data analytics, outcomes) for real-world digital mobility assessment; to validate digital outcomes in predicting clinical outcome in chronic obstructive pulmonary disease, Parkinson’s disease, multiple sclerosis, proximal femoral fracture recovery and congestive heart failure; and, to obtain key regulatory and health stakeholder approval for digital mobility assessment. The objectives address the call directly by linking digital assessment of mobility to clinical endpoints to support regulatory acceptance and clinical practice. MOBILISE-D consists of 35 partners from 13 countries with long, successful collaboration, combining the requisite expertise to address the technical and clinical challenges. To achieve the objectives, partners will jointly develop and implement a digital mobility assessment solution to demonstrate that real-world digital mobility outcomes can successfully predict relevant clinical outcomes and provide a better, safer and quicker way to arrive at the development of innovative medicines. MOBILISE-D's results will directly facilitate drug development, and establish the roadmap for clinical implementation of new, complementary tools to identify, stratify and monitor disability, so enabling widespread, cost-effective access to optimal clinical mobility management through personalised healthcare.


Alma Mater Studiorum - Universita Di Bologna 855 665 €
Amgen 0,00 €
Amgen Ltd. 0,00 €
Astrazeneca AB 0,00 €
Bayer AG 0,00 €
Centre Hospitalier Universitaire Montpellier 464 685 €
Christian-Albrechts-Universitaet ZU Kiel 1 072 069 €
Ecole Polytechnique Federale DE Lausanne 993 625 €
Eresearch Technology Inc. 0,00 €
Friedrich-Alexander-Universitaet Erlangen-Nuernberg 897 864 €
Fundacion Privada Instituto de Salud Global Barcelona 1 614 656 €
Grunenthal GmbH 0,00 €
Icon Clinical Research Ltd. 0,00 €
Imperial College of Science Technology and Medicine 390 540 €
Ixscient Ltd. 464 000 €
Katholieke Universiteit Leuven 831 661 €
Mcroberts B.V. 519 021 €
Merck KGaA 0,00 €
Norges Teknisk-Naturvitenskapelige Universitet Ntnu 2 261 649 €
Novartis Pharma AG 0,00 €
Pfizer Ltd. 0,00 €
Robert Bosch Gesellschaft FUR Medizinische Forschung mbH 2 432 796 €
Sanofi-Aventis Recherche & Developpement 0,00 €
Sheffield Teaching Hospitals NHS Foundation Trust 0,00 €
Takeda Development Centre Europe Ltd. 0,00 €
Takeda Pharmaceuticals International AG 0,00 €
Teva Pharmaceutical Industries Ltd. 0,00 €
THE Foundation FOR Medical Research Infrastructural Development AND Health Services Next TO THE Medical Center TEL Aviv 1 117 625 €
The Newcastle Upon Tyne Hospitals NHS Foundation Trust 0,00 €
The University of Sheffield 2 092 966 €
Universita Degli Studi Di Sassari 428 750 €
Universitatsklinikum Erlangen 1 125 055 €
Universitat Zurich 532 500 €
Universita Vita-Salute SAN Raffaele 704 105 €
University College Dublin, National University of Ireland, Dublin 1 551 550 €
University of Newcastle Upon Tyne 3 816 442 €
University of Northumbria AT Newcastle 432 261 €
Velocity Clinical Research Grosshansdorf GmbH 796 413 €

https://cordis.europa.eu/project/id/820820

Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.